[1] Bairey M,Shaw LJ,Reis SE,et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation(WISE) Study:Part Ⅱ:gender differences in presentation,diagnosis,and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease[J].JAm Coll Cardiol,2006,47(3s1):21-29.[2] Klocke FJ,Baird MG,Lorell BH,et al.ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)[J].J Am Coll Cardiol,2003,42(7):1318-1333.[3] 国家卫生和计划生育委员会.2013中国卫生和计划生育统计年鉴[M].北京:中国协和医科大学出版社,2013.[4] Mosca L,Appel LJ,Benjamin EJ,et al.Evidence-based guidelines for cardiovascular disease prevention in women[J].Circulation,2004,109(5):672-693.[5] Johnson BD,Shaw LJ,Buchthal SD,et al.Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease:results from the National Institutes of Health-National Heart,Lung,and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation(WISE)[J].Circulation,2004,109(24):2993-2999.[6] Maseri A.Women's Ischemic Syndrome Evaluation:current status and future research directions:report of the National Heart,Lung and Blood Institute Workshop:October 2-4,2002:perspective:new frontiers in detection of ischemic heart disease in women[J]. Circulation,2004,109(6):e62-e63.[7] 郭丽君.冠状动脉功能学评价与女性心肌缺血[J].中国心血管杂志,2015,20(4):247-249.[8] Pijls NH,Van Schaardenburgh P,Manoharan G,et al.Percutaneous coronary intervention of functionally nonsignificant stenosis:5-year follow-up of the DEFER Study[J].J Am Coll Cardiol,2007,49(21):2105-2111.[9] Schepis T,Benz K,Haldemann A,et al.Prognostic value of stress-gated 99m-technetium SPECT myocardial perfusion imaging:risk stratification of patients with multivessel coronary artery disease and prior coronary revascularization[J].J Nucl Cardiol,2013,20(5):755-762.[10] 付瑛,王蒨.冠心病危险度分层的无创性影像技术研究进展[J].心肺血管病杂志,2014,33(2):305-307.[11] 朱传明,杨淑贞,邱进,等.三磷酸腺苷二钠负荷心肌灌注显像在冠心病诊治中的临床应用[J].实用医技杂志,2013,20(6):594-596.[12] 李家俊,田月琴,何作祥.腺苷及选择性A2a受体激动剂regadenoson心肌负荷试验[J].中华核医学与分子影像杂志,2012,32(1):75-78.[13] 刘诗燕,蒋婷,袁丽萍,等.三磷酸腺苷负荷试验致过敏反应一例[J].华西医学,2015,30(5):994-995.[14] 谢梦梦,张遵城,董萍,等.腺苷负荷99mTc-MIBI心肌灌注显像在更年期女性冠心病中的诊断价值[J].实用医学杂志,2013,29(22):3703-3704.[15] 赵娜,宋丽萍.门控心肌灌注显像对冠状动脉粥样硬化性心脏病的诊断及评估价值[J].解放军医学院学报,2014,35(1):52-55.[16] Kapur A,Latus KA,Davies G,et al.A comparison of three radionuclide myocardial perfusion tracers in clinical practice:the ROBUST study[J].Eur J Nucl Med Mol Imaging,2002,29(12):1608-1616. |